NHC · Insider Trading
National Healthcare Corp.
Every open-market purchase and sale reported by NHC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Vicki L Dodson | Sr.VP Patient Srvcs | Sell | −4,834 | −$1.09M |
| 2026-09-14 | Brian F Kidd | SVP, CFO | Sell | −6,813 | −$1.54M |
| 2026-09-14 | Josh A McCreary | Senior VP & General Counsel | Sell | −2,719 | −$609.67K |
| 2026-09-02 | Ben Anderson Flatt Sr | Senior VP & CIO | Sell | −7,000 | −$1.59M |
| 2026-08-28 | David R. Gifford | Director | Sell | −1,779 | −$401.02K |
| 2026-08-21 | David R. Gifford | Director | MIXED | +1,788 | +$36 |
| 2026-08-20 | Stephen Fowler Flatt | CEO | Sell | −1,500 | −$355.62K |
| 2026-08-17 | David R. Gifford | Director | M | +1,021 | +$175.02K |
| 2026-06-23 | Emil E Hassan | Director | Sell | −5,937 | −$1.19M |
| 2026-06-18 | Emil E Hassan | Director | Sell | −1,563 | −$312.56K |
| 2026-06-18 | Brian F Kidd | SVP, CFO | G | −500 | — |
| 2026-06-10 | Robert G Adams | Director | MIXED | — | +$276.76K |
| 2026-06-02 | Lisa Piercey | Director | Buy | +949 | +$174.86K |
| 2026-05-27 | Ben Anderson Flatt Sr | Senior VP & CIO | MIXED | +1,261 | −$160.44K |
| 2026-05-22 | Richard F Laroche Jr | Director | Sell | −7,500 | −$1.46M |
| 2026-05-22 | Stephen Fowler Flatt | CEO | G | −26 | — |
| 2026-05-20 | Timothy J. Shelly | Sr.VP Operations | Sell | −1,853 | −$365.44K |
| 2026-05-18 | Brian F Kidd | SVP, CFO | MIXED | +1,366 | −$198.70K |
| 2026-05-18 | Stephen Fowler Flatt | CEO | MIXED | +1,508 | −$328.12K |
| 2026-05-08 | William A. Adams | Director | A | +7,500 deriv. | — |
| 2026-05-08 | Sandra Y. Trail | Director | M | +3,140 | +$175.06K |
| 2026-05-07 | William A. Adams | Director | A | +7,500 deriv. | — |
| 2026-05-07 | David R. Gifford | Director | A | +7,500 deriv. | — |
| 2026-05-07 | Lisa Piercey | Director | A | +7,500 deriv. | — |
| 2026-05-07 | Richard F Laroche Jr | Director | A | — | — |
| 2026-05-07 | James Paul Abernathy | Director | A | — | — |
| 2026-05-07 | Sandra Y. Trail | Director | A | — | — |
| 2026-05-07 | Emil E Hassan | Director | A | — | — |
| 2026-05-07 | Robert G Adams | Director | A | — | — |
| 2026-05-06 | Richard F Laroche Jr | Director | M | +7,500 | +$537.30K |
| 2026-05-01 | Emil E Hassan | Director | M | +7,500 | +$537.30K |
| 2026-04-24 | Vicki L Dodson | Sr.VP Patient Srvcs | MIXED | +1,147 | −$118.97K |
| 2026-04-14 | Ben Anderson Flatt Sr | Senior VP & CIO | F | −2,109 | −$372.89K |
| 2026-04-13 | Ben Anderson Flatt Sr | Senior VP & CIO | MIXED | +1,825 | −$136.12K |
| 2026-03-18 | Vicki L Dodson | Sr.VP Patient Srvcs | MIXED | +1,700 | −$134.12K |
| 2026-03-16 | Stephen Fowler Flatt | CEO | M | +1,853 | +$99.95K |
| 2026-03-16 | Brian F Kidd | SVP, CFO | M | +1,853 | +$99.95K |
| 2026-03-10 | James Paul Abernathy | Director | M | +3,140 | +$175.06K |
| 2026-03-06 | Vicki L Dodson | Sr.VP Patient Srvcs | MIXED | +1,341 | −$138.18K |
| 2026-03-06 | Timothy J. Shelly | Sr.VP Operations | MIXED | +1,853 | −$191.18K |
| 2026-03-06 | Ben Anderson Flatt Sr | Senior VP & CIO | MIXED | +4,091 | −$421.63K |
| 2026-03-06 | Brian F Kidd | SVP, CFO | MIXED | +2,053 | −$211.80K |
| 2026-03-06 | Josh A McCreary | Senior VP & General Counsel | MIXED | +1,298 | −$145.61K |
| 2026-03-03 | Stephen Fowler Flatt | CEO | A | +3,090 | — |
| 2026-03-03 | Josh A McCreary | Senior VP & General Counsel | A | +1,458 | — |
| 2026-03-03 | Ben Anderson Flatt Sr | Senior VP & CIO | A | +1,342 | — |
| 2026-03-03 | Vicki L Dodson | Sr.VP Patient Srvcs | A | +1,082 | — |
| 2026-03-03 | Timothy J. Shelly | Sr.VP Operations | A | +1,294 | — |
| 2026-03-03 | Brian F Kidd | SVP, CFO | A | +1,507 | — |
| 2026-03-03 | Stephen Fowler Flatt | CEO | MIXED | +1,415 | −$160.47K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| NATIONAL HEALTH CORP | 10%+ Owner | 1,030,887 | $217.57M |
| Robert G Adams | Director | 430,341 | $90.82M |
| W Andrew Adams | Director | 304,979 | $64.37M |
| Richard F Laroche Jr | Director | 235,760 | $49.76M |
| Robert Michael Ussery | President & COO | 158,460 | $33.44M |
| Emil E Hassan | Director | 65,595 | $13.84M |
| Stephen Fowler Flatt | CEO | 65,487 | $13.82M |
| James Paul Abernathy | Director | 43,302 | $9.14M |
| Brian F Kidd | SVP, CFO | 23,183 | $4.89M |
| Ben Anderson Flatt Sr | Senior VP & CIO | 18,636 | $3.93M |
| Vicki L Dodson | Sr.VP Patient Srvcs | 10,725 | $2.26M |
| Sandra Y. Trail | Director | 10,640 | $2.25M |
| Josh A McCreary | Senior VP & General Counsel | 10,047 | $2.12M |
| Timothy J. Shelly | Sr.VP Operations | 1,294 | $273.10K |
| David R. Gifford | Director | 1,030 | $217.38K |
| Lisa Piercey | Director | 949 | $200.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NHC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.